

8th Annual HERAPIES March 14, 2018 | Amsterdam, The Netherlands

8th Annual ADVANCERD THERAPIES MARCH 14, 2018

WELCOME AND STATE OF THE INDUSTRY REMARKS

Janet Lynch Lambert


CEO, Alliance for Regenerative Medicine



- The Alliance for Regenerative Medicine (ARM) is the only international organization specifically focused on issues facing the regenerative medicine sector, including gene therapy, cell therapy, and tissue engineering.
- ARM's 290+ global member organizations include small and large therapeutic companies, non-profit research institutions, patient organizations, and tool and technology providers.
- ARM convenes, connects, and advocates for the sector.
- Working with our members and policymakers, we foster investment, research & development, and successful commercialization of safe, effective, and transformational therapies for patients around the world.



- Advocate for clear, predictable and harmonized regulatory and review pathways
- Enable market access and value-based reimbursement policies
- Address industrialization and manufacturing hurdles
- Conduct key stakeholder outreach, communication, and education
- Facilitate sustainable access to capital and identify sources of potential public funding



Position paper released today, responding to EMA & EC's Oct 2017 action plan to foster ATMP development via improved regulatory framework

ARM's recommendations:

- **R&D**: pragmatic approach on innovative manufacturing models or use of Master Files; GMO requirements; regulatory convergence, industry-wide standards
- **Regulatory processes**: ATMP certification for non-SMEs; increased sponsor-agency interaction; guidance on IMPD & MAA structure
- **Hospital exemption**: increased guidance on scope and requirements; increased transparency; educational activities
- **Funding, investment & market access**: increase available risk capital; address market access barriers to ATMP adoption by enhanced dialogue with HTA and payers to seek pragmatic solutions



ARM's European Regulatory & Policy Priorities

Accomplishments: 2017

Regulatory

- Position paper on Hospital Exemption
- Drove publication of multi-EU organization position paper on GMO requirements for clinical trials with ATMPs
- Contributed to the review of the Blood and Cells & Tissues Directives and recommended potential improvements

Reimbursement

- Educated Members on latest developments in P&R environment that could impact ATMPs
- Advanced position and messaging on key issues
- Demonstrated thought leadership and engaged key stakeholders on P&R

Looking ahead: 2018 priorities

Regulatory

- Contribute to development and finalization of key ATMP guidelines, e.g. guideline on comparability for ATMPs
- Promote pan-EU convergence of requirements & implementation for HE, GMO, GMP, Blood/Tissues & Cells Directives

Reimbursement

- Develop principles of ARM-endorsed global value framework
- Identify key market access enablers for ATMPs and engage with HTA and payers in major EU markets to seek their adoption



Advanced Therapies Summit: Amsterdam 2018








- Sector-specific statistics and trends from 850+ regenerative medicine companies worldwide.
- **Data includes** industry financings (overall, by tech type, and by financing type), partnerships and other deals, clinical milestones, clinical trial figures (by phase and tech type), and more.
- Global & Europe-specific information available.






Major Therapeutic Platforms & Enabling Technologies

- Advanced cells: Modified T-cells; Hematopoietic stem cells; iPSCs; MSCs; adult progenitor cells (neural, liver, cardiac); etc.
- **Cell-based immunotherapies:** T-cells; CAR-T; TCR; NK cells; TILs; MILs; Gamma Delta cells, Dendritic vaccines; etc.
- Novel and synthetic gene delivery vehicles: AAV; LV; RV; AD; etc.
- **Genome editing:** CRISPR/Cas, next-gen CRISPR tech; TALENs; ZFNs; Homologous Recombination; etc.
- **Next-gen expression constructs:** novel capsids; innovative regulatory elements, including synthetic promoters that enable specificity, strength, and improve capacity; inducible elements to regulate gene expression temporally or in response to external stimuli; molecular kill switches to improve safety; etc.








European- & Israeli-Based Clinical Trials by Therapeutic Category

ALLIANCE

Regenerative Medicine



*As of end 2017 Data provided by: informa

Europe: Cell-Based Immuno-Oncology

Major companies and research institutions in this space in Europe & Israel:

<u>CAR-T</u>

- Autolous Ltd. (U.K.)
- Cellectis (France)
- Celyad (Belgium)
- *Immatics (Germany)*
- Juno Therapeutics (Germany)
- MediGene (Germany)
- Novartis / UPenn / Oxford BioMedica
- University College London (U.K.)

Gamma Delta Cells

- Gamma Delta Therapeutics (U.K.)
- TC BioPharm (U.K.)

TCRs and Modified T Cells

- AmBTU (Netherlands)
- Adaptimmune (U.K.)
- Immatics (Germany)
- Immunocore (U.K.)
- Juno Therapeutics (Germany) •
- Kiadis Pharma (Netherlands)
- PDC*Line (France)
- Zelluna Immunotherapy (Norway)

TILs and MILs

- AmBTU (Netherlands)
- Tilt Biotherapeutics (Finland)

<u>NK cells</u>

- Celyad (Belgium)
- Gamida Cell Ltd. (Israel)
- Glycostem (Netherlands)
- Lokon Pharma (Sweden)
 - Orbsen Therapeutics (Ireland)



Major companies in this space in Europe & Israel:

AAV Vectors

- Allergan (Ireland)
- Arthrogen (Netherlands)
- CEVEC (Germany)
- CombiGene (Sweden)
- Esteve (Spain)
- Genethon (France)
- Gensight Biologics (France)
- HORAMA (France)
- Lysogene (France)
- NightstaRx (U.K.)
- Quethera (U.K.)
- Shire (Ireland)
- Spark Therapeutics Ireland (Ireland)
- Treeway (Netherlands)
- uniQure (Netherlands)
- Viralgen (Spain)
- Vivet Therapeutics (France)

Lenti/Retroviral Vectors

- Adaptimmune (U.K.)
- Cellectis (France)
- Celyad (Belgium)
- CEVEC (Germany)
- EMD Serono (Germany)
- Finvector (U.K.)
- Genenta Science (Italy)
- GSK (U.K.)
- Immunocore (U.K.)
- Juno Therapeutics (Germany)
- Medigene (Germany)
- MolMed (Italy)
- Novartis (Switzerland)
- Orchard Therapeutics (U.K.)
- Oxford BioMedica (U.K.)
- VIVEbioTECH (Spain)

Adenoviral Vectors

- Cell Medica (U.K.)
- CEVEC (Germany)
- Finvector (U.K.)

Genome Editing

- Cellectis (France)
- CRISPR Therapeutics (Switzerland)
- Hphar (Belgium)
- LogicBio (Israel)

Enabling Platforms

- Novasep (France)
- PharmaCell (Netherlands)
- Synpromics (U.K.)



Europe: Gene Therapy & Genome Editing



Near-Term European Sector Commercial Progress

Near term:

- **bluebird bio Lentiglobin gene therapy** MAA filing expected by EOY 2018
- Gilead / Kite Pharma's Yescarta CAR T-cell therapy approved in U.S. 18 Oct; MAA expected early 2018
- Kiadis ATIR101 T-cell immunotherapy conditional EU approval expected mid-2018; EU launch 2019
- MolMed's Zalmoxis, currently reimbursable in Germany and as of 1 March, in Italy
- Novartis's Kymriah CAR T-cell therapy approved in U.S. 30 Aug; MAA submitted to EMA 6 Nov
- Spark Therapeutics' LUXTURNA gene therapy approved in U.S. 19 Dec; MAA submitted to EMA 31 July
- **TiGenix Cx601 allogeneic cell therapy** EMA CHMP endorsement 15 Dec; pending approval early 2018



Total Global Financings: 2017

€6.1 Billion Total Amount Raised in 2017

€3.4 Billion raised in 2016

€3.7 Billion Gene & Gene-Modified Cell Therapy €1.4 Billion raised in 2016

€362.5 Million Tissue Engineering

€345.6 Million raised in 2016

Data provided by: informa

€3.3 Billion Cell Therapy

€1.5 Billion raised in 2016

** Please note: total amount raised represents sector-wide figures; some companies are active in more than one technology group.
*** Data does not include M&A transactions

ALLIANCE for Regenerative Medicine

Total Europe/Israeli Financings: 2017

€1.2 Billion Total Amount Raised in 2017

46% increase from 2016

€731.8 Million Gene & Gene-Modified Cell Therapy 126% increase from 2016

€86.1 Million Tissue Engineering

49% decrease from 2016


€648.9 Million Cell Therapy

40% increase from 2016

 ** Please note: total amount raised represents sector-wide figures; some companies are active in more than one technology group.
 *** Data does not include M&A transactions

ALLIANCE for Regenerative Medicine

Data provided by: informa



Data provided by: informa

Significant European/Israeli Corporate Partnerships & Public Financings: 2017

Follow-On Financings

- *uniQure* €74.2M 27 Oct
- Adaptimmune €53.5M 27 March
- VBL Therapeutics €15.3M 16 Nov
- *Pluristem* €14.1*M* 25 Jan
- *Pluristem* €12.2*M* 31 Oct

PIPES/Private Placements:

- Adaptimmune €34.1M 10 April
- GenSight €20M 23 June
- Kiadis Pharma €18M 10 Oct
- Co.don €14.9M 19 Oct

IPOs:


• *NightStar* €70.1*M* – 2 Oct

Corporate Partnerships / Collaborations

- Lonza & Sanofi form €270M joint venture, all upfront 27 Feb
- NanoCarrier €93.4M agreement with VBL Therapeutics, €9.9M upfront – 6 Nov
- Oxford BioMedica €81.2M agreement with Novartis, €6.5M upfront 6 July
- Celyad €78M agreement with Novartis 2 May

Venture & Private Equity Financings:

- Orchard Therapeutics €89.3M Series B 20 Dec
- CellMedica €59.4M Series C 16 March
- Xeltis €42.9M Series C 15 Nov
- Nouscom €39.6M Series B 6 Nov
- LogicBio €36.6M Series B 28 June
- *NightStar* €36.6*M* 29 *June*
- Gamida Cell €32.5M 16 June



Regenerative Medicine

We are experiencing a turning point for the sector:

• Significant product approvals; with potentially many more to follow near-term

Key Takeaways

Regenerative Medicine

- Growing public awareness and anticipation
- Financial maturity, broad and sustained investor interest

Brings heightened emphasis on readiness in key areas:

- Reimbursement, market access
- Regulatory convergence and sector-supportive initiatives
- Industrialization and manufacturing

